Business
-
Dutch intranasal vaccine developer Mucosis has received €3.7 million from the Wellcome Trust for clinical development of its SynGEM intranasal respiratory syncytial virus (RSV) vaccine, the company said. The money will be used to fund… Read more . . .
-
MannKind Corporation has announced an agreement to develop “multiple inhaled therapeutic products” with a company called Receptor Life Sciences, described as a “newly formed entity.” MannKind says that Receptor will license MannKind’s manufacturing technology and… Read more . . .
-
Theravance, Inc, which spun off from Theravance Biopharma in 2013, will now be known as “Innoviva” and will trade on NASDAQ under the symbol “INVA,” the company said. Innoviva is partnered with GSK on the… Read more . . .
-
Vectura Group has confirmed that its US partner for the VR315 fluticasone/salmeterol DPI and the VR506 generic fluticasone propionate DPI is Boehringer Ingelheim subsidiary Roxane Laboratories. The company is partnered with Sandoz on VR315 in… Read more . . .
-
Qualcomm subsidiary Qualcomm Life will design a disposable module for the Breezhaler DPI that will sense and report inhaler usage data for Novartis’s Breezhaler COPD products, including Ultibro, Seebri, and Onbrez. The Breezhaler DPIs are… Read more . . .
-
Sanofi will return development and commercialization rights for Afrezza inhaled insulin to MannKind after disapponting sales, and MannKind says that it is considering strategic options for the product. Afrezza was approved by the FDA in… Read more . . .
-
Skyepharma has announced a partnership agreement with Mundipharma for global development and commercialization of Skyepharma’s SKP-2076 ICS/LABA/LAMA fixed dose combination MDI. Mundipharma, which already markets Skyepharma’s Flutiform fluticasone propionate/formoterol fumarate MDI in Europe and a… Read more . . .
-
GlaxoSmithKline has recalled two lots of Ventolin HFA metered dose inhalers totaling 128,704 inhalers, according to an FDA enforcement report. The company initiated the voluntary recall on December 3, 2015 due to concerns about insufficient… Read more . . .
-
AstraZeneca has announced that it will acquire Takeda’s respiratory line for $575 million. According to the company, about 200 Takeda employees will transfer to AstraZeneca as part of the deal. The company is citing the… Read more . . .
-
Turing Pharmaceuticals CEO Martin Shkreli has been arrested by the Federal Bureau of Investigations for securities fraud involving illegal stock transactions when he was CEO of Retrophin Pharmaceuticals. Retrophin fired Shkreli in September 2014 and… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.